AR007898A1 - Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene. - Google Patents

Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene.

Info

Publication number
AR007898A1
AR007898A1 ARP970103183A ARP970103183A AR007898A1 AR 007898 A1 AR007898 A1 AR 007898A1 AR P970103183 A ARP970103183 A AR P970103183A AR P970103183 A ARP970103183 A AR P970103183A AR 007898 A1 AR007898 A1 AR 007898A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
nitro
amino
medicinal product
halogen
Prior art date
Application number
ARP970103183A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR007898A1 publication Critical patent/AR007898A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

El invento se refiere al empleo de derivador de sulfonamida de la fórmula general: I en donde R significa alquilo inferior, fenilo, bencilo, naftilo,piridilo o tienilo, opcionalmente sustituido por uno o mas sustituyentes de alquilo inferior,a lcoxilo inferior, alquilo inferior-carbonil-amino, halógeno,cicloalquilo, nitro, amino, metilendioxilo, fenoxilo o benciloxilo y los anillos aromáticos pueden estar sustituidos, a su vez, por nitro, halógeno oamino, R1-R4 significanhidrógeno, halógeno, hidroxilo, alquilo inferior, nitro, ciano, amino, alcoxilo inferior, benciloxilo, trifluorometilo o fenilo,opcionalmente sustituido por uno o mas sustituyentes de alquilo inferior, triflourometilo, nitro, amino ohidroxilo, y e n donde R1 y R2 o R2 y R3 juntospueden formar un anillo de benceno que opcionalmente puede estar sustituido por halógeno, trifluorometilo, nitro, alquilo inferior o alcoxilo inferior, y desus sales farmacéuticamente aceptables comoinhibidores de quinurenin-3-hidroxilasa en el control o prevención de trastornosneurodegenerativos, trastornos neurológicos resultantes.
ARP970103183A 1996-07-19 1997-07-16 Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene. AR007898A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96111660 1996-07-19
EP97105366 1997-04-01

Publications (1)

Publication Number Publication Date
AR007898A1 true AR007898A1 (es) 1999-11-24

Family

ID=26142078

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970103183A AR007898A1 (es) 1996-07-19 1997-07-16 Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene.
ARP970103182A AR007897A1 (es) 1996-07-19 1997-07-16 Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP970103182A AR007897A1 (es) 1996-07-19 1997-07-16 Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene.

Country Status (34)

Country Link
US (1) US5889026A (es)
EP (1) EP0824098B1 (es)
JP (1) JP3179050B2 (es)
KR (1) KR100235804B1 (es)
CN (1) CN1120154C (es)
AR (2) AR007898A1 (es)
AT (1) ATE207899T1 (es)
AU (1) AU719352B2 (es)
BR (1) BR9704031A (es)
CA (1) CA2210044C (es)
CO (1) CO4900064A1 (es)
CZ (1) CZ290898B6 (es)
DE (1) DE69707782T2 (es)
DK (1) DK0824098T3 (es)
ES (1) ES2164967T3 (es)
HK (1) HK1009124A1 (es)
HR (1) HRP970394A2 (es)
HU (1) HUP9701194A3 (es)
ID (1) ID19632A (es)
IL (1) IL121299A (es)
MA (1) MA24274A1 (es)
MX (1) MX9705387A (es)
NO (1) NO308657B1 (es)
NZ (1) NZ328330A (es)
PE (1) PE86398A1 (es)
PL (1) PL321201A1 (es)
PT (1) PT824098E (es)
RU (1) RU2178412C2 (es)
SG (1) SG60085A1 (es)
TR (1) TR199700659A2 (es)
TW (1) TW498067B (es)
UY (1) UY24625A1 (es)
YU (1) YU30197A (es)
ZA (1) ZA976224B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6339087B1 (en) 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
MXPA00011889A (es) * 1998-06-02 2003-04-25 Osi Pharm Inc Composiciones de pirrolo (2,3d) piridina y su uso.
CO5150201A1 (es) * 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
BR9915735A (pt) 1998-11-20 2001-09-04 Hoffmann La Roche Antagonistas receptores de ccr-3 de piperidina
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
PA8525601A1 (es) * 2000-08-21 2002-04-25 Hoffmann La Roche Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
US6680324B2 (en) * 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7375136B2 (en) * 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
MXPA04000737A (es) * 2001-07-24 2004-07-08 Richter Gedeon Vegyeszet Derivados de piperidina como antagonistas receptores de nmda.
EP1450811B1 (en) * 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
CN1620294A (zh) 2001-12-20 2005-05-25 Osi药物公司 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
US6951884B2 (en) * 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
WO2005030720A1 (ja) * 2003-09-25 2005-04-07 Shionogi & Co., Ltd. Ｎｍｄａ受容体拮抗作用を有するピペリジン誘導体
CA2543287A1 (en) * 2003-10-23 2005-05-06 F.Hoffmann-La Roche Ag Benzazepine derivatives as mao-b inhibitors
HUP0401522A2 (en) * 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
US7485637B2 (en) * 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
US8420680B2 (en) * 2007-06-29 2013-04-16 Emory University NMDA receptor antagonists for neuroprotection
US7869022B2 (en) 2007-07-18 2011-01-11 Asml Netherlands B.V. Inspection method and apparatus lithographic apparatus, lithographic processing cell, device manufacturing method and distance measuring system
EP2296658A4 (en) * 2008-05-09 2014-01-15 Univ Emory ANTAGONISTS OF NMDA RECEPTORS USEFUL FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS
US7874106B2 (en) * 2009-02-13 2011-01-25 Ykk Corporation Of America Sill flashing and end dam assembly
BR112012009123A2 (pt) * 2009-10-19 2017-09-19 Amicus Therapeutics Inc novas composições para a prevenção e/ou tratamento de distúrbios de depósito lisossômico
ES2617192T3 (es) * 2009-10-19 2017-06-15 Amicus Therapeutics, Inc. Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2099339C1 (ru) * 1990-02-06 1997-12-20 Пфайзер Инк. Производные пиперидина
FR2672286B1 (fr) * 1991-01-31 1994-11-18 Synthelabo Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique.
FR2681319B1 (fr) * 1991-09-12 1995-02-17 Synthelabo Derives de 1-(phenoxyalkyl)piperidine, leur preparation et leur application en therapeutique.
TW281670B (es) * 1993-09-02 1996-07-21 Hoffmann La Roche
ATE183184T1 (de) * 1994-01-31 1999-08-15 Pfizer Neuroprotektive chroman verbindungen
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists

Also Published As

Publication number Publication date
ID19632A (id) 1998-07-23
CZ227497A3 (cs) 1998-02-18
DK0824098T3 (da) 2002-02-18
TW498067B (en) 2002-08-11
NZ328330A (en) 1998-05-27
NO973337D0 (no) 1997-07-18
HRP970394A2 (en) 1998-06-30
CA2210044C (en) 2006-02-14
CA2210044A1 (en) 1998-01-19
US5889026A (en) 1999-03-30
SG60085A1 (en) 1999-02-22
KR980009244A (ko) 1998-04-30
PT824098E (pt) 2002-04-29
BR9704031A (pt) 1998-12-29
DE69707782T2 (de) 2002-06-20
PE86398A1 (es) 1998-12-10
HU9701194D0 (en) 1997-09-29
EP0824098B1 (en) 2001-10-31
ZA976224B (en) 1998-01-19
YU30197A (sh) 1999-12-27
TR199700659A2 (xx) 1998-02-21
NO973337L (no) 1998-01-20
ATE207899T1 (de) 2001-11-15
CO4900064A1 (es) 2000-03-27
KR100235804B1 (ko) 1999-12-15
EP0824098A1 (en) 1998-02-18
MX9705387A (es) 1998-01-31
CN1171396A (zh) 1998-01-28
IL121299A0 (en) 1998-01-04
HUP9701194A2 (hu) 1999-05-28
ES2164967T3 (es) 2002-03-01
IL121299A (en) 2001-12-23
MA24274A1 (fr) 1998-04-01
UY24625A1 (es) 2000-12-29
JPH1067742A (ja) 1998-03-10
JP3179050B2 (ja) 2001-06-25
NO308657B1 (no) 2000-10-09
PL321201A1 (en) 1998-02-02
AU719352B2 (en) 2000-05-04
HUP9701194A3 (en) 1999-06-28
CN1120154C (zh) 2003-09-03
RU2178412C2 (ru) 2002-01-20
CZ290898B6 (cs) 2002-11-13
AR007897A1 (es) 1999-11-24
HK1009124A1 (en) 1999-05-28
DE69707782D1 (de) 2001-12-06
AU2875697A (en) 1998-01-29

Similar Documents

Publication Publication Date Title
AR007898A1 (es) Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene.
CO4900053A1 (es) Derivados de sulfonamida y -n-(4-aril-tiazol-2-il) y su uso
GT200300075AA (es) Compuestos que modulan la actividad ppar y procedimientos para su preparacion (patente fraccionaria no. 1 de la solicitud no. pi-20030075)
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
CL2021002165A1 (es) Nuevos derivados de compuestos heterociclicos y uso de los mismos
DK0687268T3 (da) Spiroazacykliske derivater som substans P-antagonister
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
AR055116A1 (es) Compuestos aromaticos como agentes terapeuticos para diabetes y composiciones farmaceuticas que los contienen.
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
ATE13422T1 (de) Derivate von 1-aryl-2-aminomethyl-cyclopropancarboxamiden (z), ihre herstellung und ihre verwendung fuer die behandlung von stoerungen des zentralnervensystems.
UY31027A1 (es) Derivados de tetrahidroindol y tetrahidroindazol
AR057906A1 (es) Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta.
AR043485A1 (es) Derivados del 8'-piridinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona y 8´-pirimidinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona substituidos
WO2006071471A3 (en) 2-(2 or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
AR039256A1 (es) Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos
BR0311767A (pt) Compostos inibidores de sulfonamida substituìda da produção de beta amilóide, suas composições e usos
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
BG100883A (en) Tropane-2-aldoxine derivatives as neurotransmitter reuptake inhibitors
MX9204094A (es) Derivados de fenilalquilo, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
CO5611124A2 (es) Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos
NO20001781L (no) 3-amino-3-arylpropan-1-og lignende-derivater, deres fremstilling og anvendelse
DK0902684T3 (da) Hexahydro-pyrido (4,3-B) indolderivater som antipsykotiske lægemidler
DE69933885D1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
DK0656001T3 (da) Nye 2-substituerede indan-2-mercaptoacetylamid-tricycliske derivater til anvendelse som enkefalinasehæmmere
AR030332A1 (es) Compuestos

Legal Events

Date Code Title Description
FB Suspension of granting procedure